| |
Baseline
|
6 months
|
|---|
|
DAS28CRP
|
5.7 (5.1-6.5)
|
2.1 (1.8-2.8)
|
|
Swollen joint count (0-28)
|
10 (7.0-17)
|
0 (0-0)
|
|
Tender joint count (0-28)
|
12 (7.0-18)
|
0 (0-1.3)
|
|
Swollen joint count (0-40)
|
13 (9.0-22)
|
0 (0-0)
|
|
Tender joint count (0-40)
|
17 (11-26)
|
0 (0-3.0)
|
|
VAS doctor global (0-100 mm)
|
56 (41-73)
|
2.0 (0-10)
|
|
CRP (mg/ml)
|
15 (7.0-42)
|
7.0 (7.0-7.0)
|
|
SDAI (0.7-82)
|
37 (29-47)
|
3.1 (0.86-7.0)
|
|
IgM-RF (% positive)
|
70.7%
|
-
|
|
Anti-CCP (% positive)
|
62.7%
|
-
|
|
TSS (% positive)
|
17.3%
|
-
|
- Relevant disease markers at baseline and following 6 months of treatment. Data are expressed as median with interquartile range (IQR). Anti-CCP: anti-citrullinated protein antibody; CRP: C-reactive protein; DAS28CRP: disease activity in 28 joints, four variables, C-reactive protein based; IgM-RF: IgM rheumatic factor; SDAI: simple disease activity index; TSS: total Sharp score; VAS: visual analog scale.
